Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Chataway

Showing results (21-30 of 182) with videos related to

Pageof 19
Sort By:
BMJ Clinical Evidence|May 21, 2009
Multiple sclerosisRichard Nicholas, Jeremy Chataway
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 14, 2014
We can compare the relative efficacy of multiple sclerosis medications by examining the results of independent clinical trials: noOlga Ciccarelli, Jeremy Chataway
Journal of Neurology, Neurosurgery, and Psychiatry|January 22, 2013
Tumefactive demyelination: an approach to diagnosis and managementTodd A Hardy, Jeremy Chataway
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 12, 2013
Natalizumab therapy for multiple sclerosisJeremy Chataway, David H Miller
Clinical Pharmacology and Therapeutics|April 16, 2019
Novel Multiple Sclerosis Drugs in the PipelineFloriana De Angelis, Jeremy Chataway
Lancet (London, England)|November 4, 2011
Multiple sclerosis-quenching the flames of inflammationJeremy Chataway, David H Miller
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2017
Advancing trial design in progressive multiple sclerosisRobert J Fox, Jeremy Chataway
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 15, 2017
Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndromeWallace J Brownlee, Jeremy Chataway
Archives of Neurology|September 13, 2006
Spontaneous improvement of syringomyelia with deterioration of a Chiari type I malformation and new symptomsSean O'Riordan, John Stevens, Jeremy Chataway
British Journal of Hospital Medicine (London, England : 2005)|September 20, 2016
New oral drugs for the treatment of multiple sclerosisDeclan Chard, Anand Trip, Jeremy Chataway
Pageof 19

Showing results (21-30 of 182) with videos related to

Sort By:
Pageof 19
BMJ Clinical Evidence|May 21, 2009
Multiple sclerosisRichard Nicholas, Jeremy Chataway
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 14, 2014
We can compare the relative efficacy of multiple sclerosis medications by examining the results of independent clinical trials: noOlga Ciccarelli, Jeremy Chataway
Journal of Neurology, Neurosurgery, and Psychiatry|January 22, 2013
Tumefactive demyelination: an approach to diagnosis and managementTodd A Hardy, Jeremy Chataway
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 12, 2013
Natalizumab therapy for multiple sclerosisJeremy Chataway, David H Miller
Clinical Pharmacology and Therapeutics|April 16, 2019
Novel Multiple Sclerosis Drugs in the PipelineFloriana De Angelis, Jeremy Chataway
Lancet (London, England)|November 4, 2011
Multiple sclerosis-quenching the flames of inflammationJeremy Chataway, David H Miller
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2017
Advancing trial design in progressive multiple sclerosisRobert J Fox, Jeremy Chataway
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 15, 2017
Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndromeWallace J Brownlee, Jeremy Chataway
Archives of Neurology|September 13, 2006
Spontaneous improvement of syringomyelia with deterioration of a Chiari type I malformation and new symptomsSean O'Riordan, John Stevens, Jeremy Chataway
British Journal of Hospital Medicine (London, England : 2005)|September 20, 2016
New oral drugs for the treatment of multiple sclerosisDeclan Chard, Anand Trip, Jeremy Chataway
Pageof 19